23 December 2020 : Clinical Research
Safety and Efficacy of Therapeutic Erythrocytapheresis Treatment in Chronic Mountain Sickness Patients in Shigatse, Tibet, China
Mingyuan NiuBCD, Shekhar SinghEF, Ma MiB, Pian BianB, Zhuoga DejiAB, Duoji MimaA, Xiankai LiACEGDOI: 10.12659/MSM.927853
Med Sci Monit 2020; 26:e927853
Table 4 Echocardiographic measurement in CMS patient before and after TEA.
| Before TEA | After TEA | P value | |
|---|---|---|---|
| Diameter of (cm) | |||
| Left atrium | 3.2±0.5 | 3.3±0.5 | >0.05 |
| Left ventricle | 4.4±0.5 | 4.6±0.4 | <0.01 |
| Right atrium | 3.7±0.8 | 3.6±0.5 | >0.05 |
| Right ventricle | 3.7±0.7 | 3.6±0.6 | >0.05 |
| Aorta (cm) | 3.0±0.4 | 3.0±0.4 | >0.05 |
| Pulmonary artery (cm) | 2.3±0.4 | 2.4±0.4 | >0.05 |
| Pulmonary pressure (mmHg) | 38.7±11.2 | 40.3±14.1 | >0.05 |
| LVEF (%) | 63±7 | 65±4 | >0.05 |
| LVFS (%) | 34±5 | 35±7 | >0.05 |
| LVEF – left ventricular ejection fraction; LVFS – Left ventricular fractional shortening. | |||